. Author manuscript; available in PMC: 2016 Apr 15.

Published in final edited form as: Toxicol Appl Pharmacol. 2015 Feb 21;284(2):180–187. doi: 10.1016/j.taap.2015.02.013

Table 3.

Distribution of urinary miRNAs in study groups

miRNA ID	1 Control	2 APAP Therapeutic	3 APAP Overdose
miR-940	35.2 (9.4-97.3)	25.3 (5.4-63.7)	104.1^b (19.9-634.4)
miR-375	3.1 (0.2-16.0)	2.0 (0.2-6.2)	10.7^b (0.8-50.0)
miR-302a	1.3 (0.2-117.6)	0.8 (0.2-1.6)	17.8^a,b (1.7-295.5)
miR-9-3p	135.3 (55.3-474.8)	436.2 (96.7-834.5)	1,186.3^a (133.3-4,371.2)

Note: The relative miRNA levels are expressed as relative concentration, normalized to three endogenous miRNAs (miR-7, miR-671-3p, and miR-943), and presented as median (range). For Dunn's pairwise comparison:

p<0.05 for Group 3 vs 1

p<0.05 for Group 3 vs 2.

One altered miRNA (miR-375) overlapped between serum and urine samples.